Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From CSL Limited
Around 100 executives highlight the hot areas to watch on the R&D front in 2021. From cancer to CNS and from regenerative medicine to real world data, expectations are high on many fronts.
Office of Prescription Drug Promotion issued just six letters citing companies for improper drug promotion in 2020, including the placement of safety information in an email and making unfounded COVID-19 claims. New research projects focus on celebrity endorsements, medical conference materials.
The gene therapy EtranaDez for hemophilia B placed on clinical hold after a patient was diagnosed with liver cancer, but UniQure points to that patient’s extensive history of liver disease.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
- Diagnostic Equipment & Supplies
Diagnostic Imaging Equipment & Supplies
- Digital Imaging
- Other Names / Subsidiaries
- CSL Behring
- CSL Behring Mexico
- CSL Biotherapies
- CSL Bioplasma
- Wuhan Zhong Yuan Rui De Biological Products
- Calimmune, Inc.
- Vitaeris Inc.
- Zenyth Therapeutics Ltd.
- CSL, Ltd.